The official blog of the Lung Institute.

This Week in Lung Disease: Brexit May Affect UK’s Air Pollution; Pigeons to the Rescue

30 Jun 2016
| Under Lifestyle | Posted by
| 1 Comment
This Week in Lung Disease 3

The internet is an odd place, filled with cat videos and pop-up ads. Sometimes it can be difficult to find the important news and issues surrounding chronic lung disease. That’s why the Lung Institute searches the internet for the top lung disease news stories with our series, “This Week in Lung Disease.”

UK’s Brexit Brings Dark Smog Cloud of Uncertainty

The United Kingdom’s decision last week to leave the European Union could lead to a shakeup in environmental regulation. Prior to the UK’s vote to leave the EU, known as “Brexit”, The Guardian wrote that according to environmental professionals, the UK’s environmental crisis could get worse if the Brexit were to occur.

Prior to the vote, the UK has historically had air pollution levels above legal limits in many cities. In a poll of almost 1,200 environmental professionals, 48 percent believe air quality standards in the UK will get worse if they left the EU, with only 4 percent believing air quality would get better and 42 percent believing it would stay the same. Clearly, this is not good news for those living with lung disease in the UK.

Check out the rest of this lung disease news story here.

Measuring Air Pollution is for the Birds

Continuing with pollution levels in Europe, Readwrite.com, recently wrote about how technology is helping to measure air pollution more accurately. Many technology companies and startups are working on ways the internet can help map pollution levels using  sensors and other wearable tags.

One of the more unique methods comes from Plumelabs, a Paris-based startup, which involves racing pigeons. In March, Plumelabs released the pigeons wearing pollution-sensors on their backs to monitor London’s air pollution levels. This data will then be used to help create urban pollution forecasts to help those living in cities.

To learn more about this pollution tracking method and more traditional tracking methods, click the link.

In-Home COPD Care Could Be Financially Beneficial

Ontario, Canada is looking into ways of bringing care for people with chronic obstructive pulmonary disease (COPD) closer to home. The Canadian Foundation for Healthcare Improvement released a report showing that the number of COPD-related hospitalizations can be reduced by 80 percent when healthcare is provided in the patient’s home.

In Ontario, there were more than 27,000 COPD-related hospitalizations recorded between 2013-2014, with an average price tag on taxpayers of roughly $1,000 per day, per patient. According to the study, COPD is now the No. 1 reason for hospitalizations in Canada.

With nurses traveling to the patient’s home for COPD care, it can save Canadian taxpayers money and help the patients stay emotionally upbeat.

To learn more, check out the rest of the story via the Toronto Star.

Eighth Coal Miner Diagnosed with Black Lung in Queensland

Queensland, Australia has been in the news lately as more coal miners are being diagnosed with pneumoconiosis. Recently, another coal miner – the eighth since May of last year – has been diagnosed with black lung disease working in Central Queensland. This comes off the heels as Australian officials call for more regulation to protect the health of those working in coal mines.

For more on this story, go to the Australian Broadcasting Company’s website.

Keep checking-in with us for the latest lung disease news. If you or someone you know has a chronic lung disease, remember there is hope. Here, at the Lung Institute, we specialize in cellular therapys for those with lung disease such as COPD, pulmonary fibrosis and interstitial lung disease. For more information about the Lung Institute or cellular therapy, please contact one of our patient coordinators by calling 888-745-6697 today.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.